(Incorporated in Delaware)

We are a clinical oncology company developing radiopharmaceuticals to treat solid tumors.

Our lead drug candidates are:

-Ac-AKY-1189 to treat cancers that express Nectin-4 – We are now enrolling 150 patients in a Phase 1B trials with preliminary results expected in the first quarter of 2027, and

–Ac-AKY-2519 to treat tumors that express B7-H3 – We plan to submit an IND filing in 2026.

Note: Net loss and revenue are for the 12 months that ended Sept. 30, 2025.

(Note: Aktis Oncology priced its recently upsized IPO at $18.00 – the top of its $16.00-to-$18.00 range – and sold 17.65 million shares – the number of shares in the prospectus – to raise $317.7 million on Thursday night, Jan. 8, 2026. Background: Aktis Oncology increased its IPO’s size by  50 percent to 17.65 million shares – up from 11.78 million shares originally – and kept the price range at $16.00 to $18.00 to raise $300.05 million – if priced at the $17.00 mid-point of its range. Under the IPO’s original terms, Aktis Oncology was set to raise $200.18 million. Background: Aktis Oncology disclosed the terms for its IPO in an S-1/A filing dated Jan. 5, 2026: The company is offering 11.78 million shares (11,775,000 shares) at a price range of $16.00 to $18.00 to raise $200.18 million, if priced at the $17.00 mid-point of its range. Background: Aktis Oncology filed its S-1 for its IPO on Dec. 19, 2025, without disclosing the terms. Estimated proceeds are $100 million, a placeholder figure.)